Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 12/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022946 | 1.00 | ACACB (0.55) | ACACBOPRM1OPRD1OPRK1ESR1 | |
| SCHEMBL15918728 | 0.86 | OPRM1 (0.44) | ACACBOPRM1OPRD1OPRK1ESR1 | |
| SCHEMBL9932242 | 0.84 | SMN1; SMN2 (0.57) | ACACBKMT2AALDH1A1LMNA | |
| SCHEMBL9932241 | 0.84 | SMN1; SMN2 (0.57) | ACACBKMT2AALDH1A1LMNA | |
| SCHEMBL27587682 | 0.83 | HSD17B10 (0.56) | ACACBKMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL14097766 | 0.83 | HSD17B10 (0.56) | ACACBKMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL16481215 | 0.83 | ACACB (0.47) | ACACBOPRM1OPRD1OPRK1ESR1 | |
| SCHEMBL15022611 | 0.79 | ACACB (0.54) | ACACBESR1PDCD1ESR2CD274 | |
| SCHEMBL6966307 | 0.79 | ACACB (0.54) | ACACBESR1PDCD1ESR2CD274 | |
| SCHEMBL6421498 | 0.79 | ESR1 (0.48) | ACACBOPRM1OPRD1OPRK1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794586-B1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2794586-B1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2794586-A1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8530460-B2 | Azetidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-8530460-B2 | Azetidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| WO-2013092616-A1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158004-A1 | Azetidine Derivatives | GPR119, LIPE, LPL | ACACB 870/4885OPRM1 873/4885OPRD1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.